Johnson & Johnson
featured
The "Fast Money" traders share their final trades of the day.
» Read More
 2.160x105.jpg?v=1369079618 "Cramer: Invest Like the Ridiculously Rich")
More
-
The Dow Jones Industrial Average closed at a record high, but slipped below 14,000 after trading above the milestone earlier in the session. Traders remained optimistic that the market will power higher. "We're not going to stop at 14,000; it's just an arbitrary number," said Gordon Charlop, president of Walter J. Dowd.
-
Johnson & Johnson Tuesday said second-quarter profit rose on higher sales of medical devices and prescription drugs, beating Wall Street expectations on especially strong demand in overseas markets.
-
The headline might say, "Johnson & Johnson Beats the Street," but investors are looking behind it and that's what is pushing this Dow component down this morning. For example, JNJ says its topline growth would have been just 3.6% instead of 13% if it had not bought Pfizer's consumer health care business last year for $16.6 billion. JNJ is kind of a three-pronged hybrid: pharma, medical devices and consumer healthcare.
-
The CNBC Executive Leadership Awards honor executives who have shown exemplary leadership, inspiration and innovation. More than 300 business leaders attended the third annual gala at the Pierre Hotel in New York Wednesday night and paid special tribute to legendary Federal Reserve Board Chairman Alan Greenspan.
-
Earnings news is helping set the tone as some big positive reports are countering weakness in stocks ahead of inflation data.
-
Corporate America is on a share buyback binge, fueling concerns that U.S. companies are masking underlying business problems and trying to pump up their executives' compensation.
-
Johnson & Johnson said on Monday its board of directors approved the repurchase of up to $10 billion of its common stock.
-
Even with the July 4th holiday next week, analysts think the markets will be as jittery as ever. "The market is very nervous here," Steven Neimeth, portfolio manager at AIG SunAmerica Asset Management told CNBC.com. "Lower liquidity around the Fourth of July week could lead to greater volatility as a result of news events, whether it be the Middle East, oil or the credit markets. Any news, good or bad, is likely to have a heavy impact on the market."
-
On the surface, long-term "sensible" investor Warren Buffett and "Mad Money" trader Jim Cramer appear to have two very different styles and you wouldn't expect much agreement between them. But Stockpickr (a subsidiary of TheStreet.com) president James Altucher did some analysis of Cramer's take on Buffett's stocks and found a lot of common ground.
-
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift your money from one to the other. Luckily, Cramer knows the precise moment.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
On Wall Street, the Berkshire Hathaway chief is a god. But does he still have his mojo after all these years?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Health care company Johnson & Johnson got a ratings upgrade to "neutral." Catherine Arnold, senior pharmaceuticals analyst at Credit Suisse, told “Closing Bell” why her firm lifted the company from underperform -- but is still holding off from an "overperform" rating.
-
Stocks closed flat as the markets failed to hang onto a minor afternoon rally. "As volatility starts to pick up again, people have begun to realize that the probability of the Fed easing here is very, very low -- maybe even a better probability the Fed tightens here," said Richard Bernstein, chief investment strategist at Merrill Lynch.
-
Analysts say the next couple of weeks could be rough for the stock market as investors keep a close eye on interest rates. "We're probably going to see some more selling," Sebastian Leburn, chief investment officer at Weiss Capital Management, told CNBC.com.
-
Next week is conference week and that means companies should have big news for investors. Here’s how to play it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Don't let the summer doldrums strike your portfolio. We've rounded up several five-star mutual fund managers to offer up on their latest strategies and best investment ideas.
-
Cramer thinks this index will climb another thousand points by the end of the year. Owning the stocks that should get it there could do wonders for your portfolio.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
Medtronic reported a forecast-beating 10% rise in quarterly earnings on Tuesday on strongsales of its vascular, neurology and diabetes products and improving demand for its heart rhythm devices.
-
Most analysts believe the market is due for a modest correction, but many traders are reluctant to sell in the face of strong earnings, massive liquidity and daily deals. "I don't think there's anything to be that bearish about," Stephen Leeb, research chairman for The Complete Investor, told CNBC.com. "There's no recession, valuations are basically very reasonable and there are massive amounts of cash on the sidelines."